Syros Pharmaceuticals, Inc. Common Stock
SYRS
SYRS was delisted on the 19th of March, 2025.
12 hedge funds and large institutions have $207M invested in Syros Pharmaceuticals, Inc. Common Stock in 2016 Q2 according to their latest regulatory filings, with 12 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$54.9M |
| 2 |
DM
Deerfield Management
New York
|
+$38M |
| 3 |
RG
Redmile Group
San Francisco,
California
|
+$17.2M |
| 4 |
AC
Aisling Capital
New York
|
+$16.5M |
| 5 |
BBA
Baker Bros. Advisors
New York
|
+$3.71M |
Top Sellers
SYRS Hedge Fund Activity: Q2 2016 in Review
12 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Syros Pharmaceuticals, Inc. Common Stock (SYRS) for Q2 2016, worth a combined $207M.
Buyers outnumbered sellers: 12 funds opened new SYRS positions and 0 closed out — a net gain of 12 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $54.9M.
- 12 institutional investors held Syros Pharmaceuticals, Inc. Common Stock (SYRS) as of Q2 2016, up from 0 in Q1 2016.
- Funds reported $207M of Syros Pharmaceuticals, Inc. Common Stock stock for Q2 2016.
- 12 funds opened new Syros Pharmaceuticals, Inc. Common Stock positions in Q2 2016 and 0 closed out, a net change of +12 holders.
- The largest Syros Pharmaceuticals, Inc. Common Stock buyer in Q2 2016 was Fidelity Investments, an estimated $54.9M added.
Based on aggregated 13F filings for Q2 2016.